Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Evommune, Inc.NYSE: EVMN
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$23.95M, compared with -$15.03M a year earlier. Trailing-twelve-month operating income was -$89.99M.
Context
- Operating income amounted to 623.6% of revenue in FY2025, down 376.6 pp from a year earlier.
- Operating income grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 6 analysts of -$19.98M (+75.4%) for the fiscal year ending Dec 2026, a step up from the -15.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.95M+19.4% QoQ
- Last fiscal yearDec 2025
- -$81.07M-15.8% YoY
- LTMMar 2026
- -$89.99M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.4% | -5.0% | +54.4 pp |
| 1 year | -15.8% | +75.4% | +91.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (81.07M) USD
- Year-over-year change
- -15.8%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (81.07M) | -15.8% |
| FY2024 | 2024-12-31 | (70.01M) | -85.0% |
| FY2023 | 2023-12-31 | (37.85M) | — |
Operating Income vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 operating income of -$89.99M is the 8th highest of the 10 companies compared; the peer median is -$57.93M.
- Operating income amounts to 899.9% of revenue for EVMN, versus a peer median of 34.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $100.93M | +394.5% | +149.6% | 34.7% | |
| LTM Sep 2026 | $44.15M | +162.5% | — | 16.6% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $11M | +101.8% | — | 0.4% |
| LTM Mar 2026 | -$25.89M | +61.4% | — | 33.2% | |
| LTM Mar 2026 | -$57.93M | +18.2% | — | 200.3% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | -$60.08M | +41.1% | — | — |
| LTM Mar 2026 | -$84.21M | +29.2% | — | 55.7% | |
EVMNEvommune, Inc. | LTM Mar 2026 | -$89.99M | — | — | 899.9% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$92.07M | -22.8% | — | — |
| LTM Mar 2026 | -$281.82M | -74.6% | — | 3700.9% | |
| Peer median (excluding EVMN) | -$57.93M | +41.1% | +149.6% | 34.7% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.